HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Insmed (NASDAQ:INSM) and maintained a price target of $90.
November 01, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Insmed, maintaining a price target of $90, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $90 price target by a reputable analyst suggests a positive outlook for Insmed. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100